PMC9772926_01
Patient's CD4 (cells/mm3) and VLs (copies/mL) dynamics. This figure explains the CD4 count cells' decline and the VL's rise over a period of 4 years during first-line ART (TDF 3TC EFV) with poor adherence and immunologic recovery + virologic suppression 3 months after starting effective second-line ART (TDF AZT 3TC ATV/r).
10.1177_2050313X221144209-fig1.jpg
PMC9772926_01_10.1177_2050313X221144209-fig1.jpg
fig1-2050313X221144209
The client took his ARVs and kept all his clinical appointments. Three months later, his VL (9 September 2019) was suppressed at 30 copies/mL, and his CD4 counts improved to 275/mm3 (Figure 1).